[ad_1]
Pune, January 10, 2022 (GLOBE NEWSWIRE) – The 2021 Humira market report is an extensive study of industry experts in the development of modules, arrangements, sports, and dimensions. The report also estimates existing and early market standards to predict potential market management during the forecast period 2021-2027. Humira’s research involves the widespread use of equally primary and secondary data sources. This includes research on several parameters that affect the industry, including government plans, market conditions, competitive landscape, historical data, current market trends, technological inventions, future technologies, and technological growth in related industries.
Get a sample copy of the report- https://www.absolutereports.com/enquiry/request-sample/18875325
Humira (adalimumab) is a tumor necrosis factor (TNF) blocker that reduces the effects of substances in the body that can cause inflammation.
Humira is used to treat many inflammations in adults, such as ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and a skin disease called hidradenitis suppurativa.
Humira is also used in adults and children to treat Crohn’s disease or juvenile idiopathic arthritis.
In 2014, in India, the first adalimumab biosimilar was launched at a price of US$200. Two years later, Torrent Pharmaceuticals, another Indian pharmaceutical company, launched its second biosimilar. Humira’s US patent expired in 2016.
The classification of Humira includes Humira Syringe and Humira Pen. The proportion of Humira syringes is about 78%.
Humira is widely used in ankylosing spondylitis, rheumatoid arthritis, Crohn’s disease and other diseases. Humira is used in the most proportion of ankylosing spondylitis, the proportion is…
The full story can be found on Benzinga.com
[ad_2]
Source link
